Search the Newsreel

Boston Scientific, Stryker Settle Surgical Device Patent Dispute

Boston Scientific Corp. and Stryker Corporation have reached an agreement in principle to settle their patent dispute over a surgical device used to treat chronic lower back pain. This settlement comes shortly after Boston Scientific failed to block sales of Stryker’s competing product. The …

Boston Scientific (BSX) Stock Still Looks Undervalued Following Its 58% Slump

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Boston Scientific stock has had a tough run over the past year, yet the valuation checks still lean supportive, setting up a clear tension …

Boston Scientific stock trades steadily as device maker grows revenue and prepares for next earnings

Boston Scientific (BSX) stock is trading steadily due to consistent share-price performance and revenue growth. The company, a major medical device manufacturer, is expanding its cardiovascular and neuromodulation portfolio and has reported strong double-digit revenue growth in recent periods, driven by product launches and …

Boston Scientific (BSX) Recalls Put Focus On Whether The Stock Still Looks Undervalued

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Recall driven attention on Boston Scientific stock Boston Scientific (BSX) is back in focus after a series of voluntary recalls for its CRE and …

What To Expect From Boston Beer’s (SAM) Q2 Earnings

Boston Scientific's Q2 Earnings Coming Up: Buy, Hold or Sell the Stock?

Boston Scientific BSX is slated to report second-quarter 2026 results on July 29, before the market opens. The Zacks Consensus Estimate for the company's second-quarter earnings per share (EPS) suggests 10.7% year-over-year growth to 83 cents. The estimate has remained constant in the past …

Boston Scientific (BSX) Stock Sinks As Market Gains: What You Should Know

Boston Scientific (BSX) closed at $43.19 in the latest trading session, marking a -1.33% move from the prior day. This change lagged the S&P 500's daily gain of 0.89%. At the same time, the Dow added 0.74%, and the tech-heavy Nasdaq gained 1.29%. Shares …

Boston Scientific Corp. stock outperforms competitors despite losses on the day

Shares of Boston Scientific Corp. (BSX) fell 1.33% to $43.19 on Tuesday, marking its third consecutive day of losses. Despite this decline, the stock still outperformed the broader market, as the S&P 500 Index (SPX) rose 0.89% and the Dow Jones Industrial Average (DJIA) …

Bossard Holding AG (XSWX:BOSN) (Q2 2026) Earnings Call Highlights: Strong Growth Amid Currency ...

This article first appeared on GuruFocus. Sales: CHF575.7 million in the first half of 2026, a growth of 9.7% in local currency and 5.3% in Swiss francs. Gross Profit Margin: Increased by 11.7% to CHF198.3 million, with gross margin improving from 32.5% to 34.4%. …

Boston Scientific stock advances on strong sales and margin gains

Boston Scientific's stock is advancing due to strong sales and margin gains, highlighted by a 14.5% revenue growth to $4.1 billion and a 28.7% adjusted operating margin in its latest reported quarter. The company also demonstrated strong profitability with $1.3 billion in free cash …

Boston Scientific to Combine Light Manufacturing, Global Distribution in Indiana Expansion

Boston Scientific is investing approximately $138 million in a new 500,000-square-foot facility in Plainfield, Indiana. This expansion will integrate light manufacturing with global medical device distribution, creating up to 300 jobs. The facility aims to enhance the company's logistics and production capabilities, serving as …

Boston Beer: Long-Term Demographic Challenges, Near-Term Technical Risks (SAM)

Boss Energy (ASX:BOE) Advances Amid Broad Strength Across Energy Stocks

Boston Beer: Margin Gains Can’t Replace Revenue Growth (NYSE:SAM)

Boston Scientific stock holds gains as cardiovascular revenue grows and new devices support long ter

Boston Scientific's stock stability is attributed to its cardiovascular and MedSurg portfolio expansion, marked by increased revenue and better margins from new devices. The company's focus on minimally invasive medical devices and robust revenue growth supports its market position, with significant investment in R&D …

Boston Scientific Aktie: Wachstumsziel auf 7–8,5% gesenkt

Boston Scientific stock trades steady as latest earnings highlight growth and margin focus

Boston Scientific (NYSE: BSX) has demonstrated solid financial performance, with fiscal 2025 net sales reaching approximately $16.0 billion, a 10% increase from 2024, driven by strong growth in its Cardiovascular and MedSurg segments. The company's operating income also saw significant growth, rising around 20% …

BOS Better Online Solutions Announces July 28 Virtual Investor Event on 2026 Strategy and Growth

BOS Better Online Solutions (BOSC) is hosting a virtual investor event on July 28, 2026, to discuss its 2026 execution and long-term growth strategy. The Israeli company, which integrates supply chain technologies for various sectors, aims to enhance investor transparency and strengthen relations. An …

Boston Scientific stock trades steady as cardiovascular and neuromodulation growth supports earnings

Boston Scientific's stock is supported by robust growth in its cardiovascular and neuromodulation divisions, demonstrating double-digit revenue expansion and improved margins. The company benefits from a diversified product portfolio, ongoing innovation in minimally invasive therapies, and strategic geographic expansion. These factors, alongside disciplined cost …

Boston Scientific Corp. stock underperforms Friday when compared to competitors

Boston Scientific Corp. (BSX) stock fell by 1.32% on Friday, closing at $44.03, underperforming its competitors and the broader market. This decline occurred during a generally negative trading session, with the S&P 500 Index dropping 1.01% and the Dow Jones Industrial Average falling 0.77%. …

Why AirBoss of America Corp. stock is sliding today

BOS Better Online Solutions (NASDAQ: BOSC) schedules July 28 virtual investor event

BOS Better Online Solutions Ltd. (NASDAQ: BOSC) announced a virtual investor event scheduled for July 28, 2026, at 10 a.m. ET. The event will provide current and prospective shareholders with an update on the company's 2026 execution and long-term growth plan, led by CEO …

Boston Scientific stock trades steadily as Q1 2026 growth and cardiology portfolio underpin valuatio

Boston Scientific's stock is trading steadily, supported by strong Q1 2026 revenue growth and expanding margins across its medical technology portfolio. The company's focus on interventional cardiology, structural heart treatments, and minimally invasive technologies, particularly with products like the WATCHMAN device, underpins its valuation …

Boston Beer Q2 Earnings Upcoming: Can It Surpass Estimates?

Boston Scientific Expands Medical Device R&D in Ireland With €75 Million Investment

Boston Scientific is investing €75 million to expand its research and development capabilities at its Galway facility in Ireland. This investment will enhance the site's role in developing next-generation cardiovascular and medical technologies, including new laboratories. The expansion aims to accelerate the development of …

Boston Scientific stock hits 52-week low at 42.24 USD By Investing.com

Boston Scientific's stock has fallen to a 52-week low of $42.24, despite an InvestingPro analysis suggesting it is undervalued with "GREAT" financial health and 17% revenue growth. This downturn follows lowered price targets from several analyst firms due to anticipated slowdowns in WATCHMAN device …

Boston Scientific Aktie: 77 auf 57 Dollar – WATCHMAN belastet

Innovation, Pricing and Brand Investments Drive Boston Beer's Growth

Price to earnings forward of Minbos Resources Limited – ASX:MNB

Boston Omaha Corporation (BOC) Gains 1.55% as Stock Tests Resistance Near $15.84 - Bullish Sentiment

Boston Scientific Aktie: Watchman bremst Wachstum

HUGO BOSS-Aktie trotzt dem Abwärtssog: Kursziel steigt trotz unaufgeregter UBS-Prognose

BOSC Q1 2026 Earnings: EPS Hits $0.11; Stock Rises on Strong Operating Performance - Guidance vs Actual

Boston Scientific Aktie: FDA stuft Orca-Ventile als Class II ein

BOSTON PIZZA ROYALTIES INCOME FUND ANNOUNCES RESULTS OF ANNUAL GENERAL AND SPECIAL MEETING VOTING

Boston Scientific Aktie: 65% Kurspotenzial trotz anhaltender Talfahrt